Tirzepatide | 10 vials

Tirzepatide is a first-in-class, 39-amino acid synthetic peptide that functions as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors . This novel "twincretin" mechanism leverages the synergistic effects of two key incretin hormones to provide metabolic benefits that surpass those of selective GLP-1 receptor agonists .

Key Specifications:

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

• Molecular Weight: 4813.53 g/mol

• Sequence Length: 39 amino acids

• Purity: ≥99%

• Half-life: Approximately 5 days (supports once-weekly administration)

Mechanism of Action: Tirzepatide activates both GIP and GLP-1 receptors, leading to:

• Glucose-dependent insulin secretion

• Reduced glucagon release

• Delayed gastric emptying

• Decreased food intake and increased satiety

Research Applications:

• Type 2 diabetes and glycemic control (SURPASS program)

• Obesity and weight management studies (SURMOUNT program)

• Obstructive sleep apnea (SURMOUNT-OSA)

• Metabolic-associated steatohepatitis (SYNERGY-NASH)

• Cardiovascular outcomes research

Research Use Only. Not for human consumption.